Thymosin Alpha 1

Thymosin Alpha 1 (Ta1/Thymalfasin/Zadaxin) is a synthetic 28-amino acid peptide identical to the naturally occurring thymic hormone. With over 11,000 patients studied across 30+ clinical trials, it holds FDA orphan drug designations for four conditions and is approved in 35+ countries worldwide. Ta1 demonstrates exceptional safety with less than 1% serious adverse events while providing comprehensive immune system modulation.

• Primary Immunodeficiencies
• Vaccine Response Enhancement
• HIV/AIDS Immune Support

Primary FDA-studied route with extensive clinical data. Maximum immune modulation through systemic circulation. Established dosing protocols from 35+ countries of clinical use.

Injectable Ta1 provides optimal bioavailability (90-95%) with rapid Tmax of 2 hours. Activates multiple TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function through systemic circulation.

Peak plasma concentration: 2 hrs. Elimination half-life: 2 hrs. Largely cleared by: ~10 hrs.

Research protocols from published literature — not dosing recommendations.

• Immunosuppressive Agents — Contraindicated: Absolute contraindication in organ transplant recipients. Fatal immune hemolytic anemia and graft rejection documented in hematopoietic stem cell transplant patients.
• Corticosteroids — Monitor Combination: Pharmacodynamic antagonism as Ta1 blocks steroid-induced thymocyte apoptosis, potentially reducing immunosuppressive effects.
• Interferon-α — Synergistic: Enhanced antiviral efficacy in hepatitis treatment with synergistic NK cell activation. Monitor for increased fever, fatigue, and neutropenia.
• Vaccines — Compatible: Intended therapeutic effect enhancing vaccine immunogenicity, particularly beneficial in elderly and immunocompromised patients.
• Chemotherapy Agents — Compatible: Protective effects against cytotoxic bone marrow damage while maintaining standard oncology monitoring protocols.

Supplies:

• Sterile water for injection (1.0 mL)
• Insulin syringes (1mL)
• Alcohol swabs
• Lyophilized Ta1 vial (1.6mg)
• Sterile work surface

1. 1Clean work area and hands thoroughly
2. 2Add 1.0 mL sterile water slowly to lyophilized powder
3. 3Inject water slowly down vial side (not directly onto powder)
4. 4Gently swirl until completely dissolved (never shake)
5. 5Final concentration: 1.6 mg/mL
6. 6Use promptly or refrigerate at 2-8°C for up to 7 days

Week 1-2: Initial immune system activation. Week 2-6: Enhanced immune function and reduced infection risk. Week 6-12: Maximum immunomodulatory benefits. Week 12+: Sustained immune support with continued use. Most effective for: Immune deficiencies, chronic infections, vaccine enhancement.

Exceptional safety profile with <1% serious adverse events across 11,000+ patients. Most common side effect: mild injection site reactions (<10%). Contraindicated in organ transplant recipients (risk of graft rejection). Monitor for hypersensitivity reactions with first dose. Not recommended during pregnancy or breastfeeding. Exceptional safety profile with <1% serious adverse events across 11,000+ patients. Most common side effect: mild injection site reactions (<10%). Contraindicated in organ transplant recipients (risk of graft rejection). Monitor for hypersensitivity reactions with first dose. Not recommended during pregnancy or breastfeeding.

Thymosin Alpha 1 should be stored at Lyophilized: -18°C, Reconstituted: 2-8°C up to 7 days.